Alec Machiels - Jan 1, 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Director
Signature: /s/ David Watson, attorney-in-fact for Alec Machiels
Stock symbol: APLS
Transactions as of: Jan 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 1/4/2023, 04:37 PM
Previous filing: Dec 19, 2022
Next filing: Jan 19, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Award	$0	+3.87K	+1.47%	$0.00	268K	Jan 1, 2023	Direct	F1
holding	APLS	Common Stock						250K	Jan 1, 2023	Indirect Owner (Bauhaus 1 LLC)	F2
holding	APLS	Common Stock						12K	Jan 1, 2023	Indirect Owner (Owned by Spouse)	F3
holding	APLS	Common Stock						150K	Jan 1, 2023	Indirect Owner (Spouse Trust)	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$0	+7.44K		$0.00	7.44K	Jan 1, 2023	Common Stock	7.44K	$51.71	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This restricted stock unit was granted on January 1, 2023. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election.
F2	The shares are held by Bauhaus 1 LLC, which LLC is held by The Irrevocable Agreement of Trust of Alec Machiels (the "Trust"). The reporting person is the managing member of Bauhaus 1 LLC and the trustee of the Trust.
F3	The shares are owned by the reporting person's spouse.
F4	On September 7, 2021, the reporting person's spouse transferred 150,000 shares of Apellis Pharmaceuticals, Inc. common stock to her trust, of which the reporting person is the trustee.
F5	This option was granted on January 1, 2023. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant.